2026-04-13T02:44:13Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4450922025-07-29T19:12:05Zcom_2072_98col_2072_378192

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies Leleu, Xavier Beksac, Meral Chou, Takaaki Dimopoulos, Meletios Yoon, Seokbeom Prince, H. Miles Pour, Ludek Shelekhova, Tatiana Chari, Ajai Khurana, Monica Zhang, Jianqi Obreja, Michaela Qi, Ming Oriol, Albert Siegel, David Universitat Autònoma de Barcelona Daratumumab Carfilzomib Multiple myeloma Weekly regimen The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)-adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option. 2020 Article Leukemia and Lymphoma ; 2020 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. https://creativecommons.org/licenses/by-nc-nd/4.0/